Kelly Arrontes combines art and science in her “Water is Life” mural Blog Post

Kelly Arrontes has completed her artistic project at the Barcelona Science Park which she began in January. Created with the sponsorship of Agbar, the mural depicts water’s four states as it runs for 125 metres along the corridor that connects the Cluster I and Cluster II buildings. Kelly Arrontes, who is legally blind as she only has 9% of normal vision, is a member of ONCE. Her “Water is Life” project won a PCB art contest which was open to the public and anonymously judged.

 

RAC1 protein could be a new therapeutic target to fight neurodegeneration in Parkinson’s disease Blog Post

A new research study reveals RAC1 protein could be a new therapeutic target to study the molecular mechanisms related to the neurodegenerative processes in Parkinson’s disease. The study, published in the online edition of the journal Molecular Neurobiology, is led by Antonella Consiglio –head of the Laboratory of Stem Cells and Neuroplasticity at the Institute of Biomedicine of the UB (IBUB) in the Barcelona Science Park and researcher at the Faculty of Medicine and Health Sciences of the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL)– and Esther Dalfo, from the Univesitat Autònoma de Barcelona and Universitat de Vic – Universitat Central de Catalunya.

 

Jaume Amat, CEO of Specipig, new president of CataloniaBio & HealthTech Blog Post

CataloniaBio & HealthTech has chosen its first president and board of directors today, after the merger of the CataloniaBio association of companies and the HealthTech Cluster last December, at an extraordinary members’ assembly. The new entity, located at the Barcelona Science Park, represents more than 170 companies, as well as collaborating stakeholders such as hospitals, research centres and universities that are leaders in R&D in biomedicine.

 

Chemotargets signs a research collaboration agreement with FDA/CDER Blog Post

The Food and Drug Administration’s Center for Drug Evaluation and Research (FDA-CDER) and Chemotargets –a spin off from the IMIM Hospital del Mar Medical Research Institut and located at the Barcelona Science Park– will work together under a 5-year Research Collaboration Agreement (RCA). The collaboration aims to enhance CDER’s safety assessments of human pharmaceuticals, supporting the FDA’s mission of protecting public health.

 

Minoryx starts a phase II/III clinical study of MIN-102 for the treatment of adrenomyeloneuropathy Blog Post

Minoryx Therapeutics –a company specialized in the development of new drugs for orphan diseases, located at the Barcelona Science Park and the TecnoCampus Mataró– announces the start of its pivotal phase II/III clinical trial of MIN-102 for the treatment of adrenomyeloneuropathy (AMN), the most frequent phenotype of X-linked adrenoleukodystrophy (X-ALD). The trial enrolls adult male patients affected by AMN, the most frequent phenotype of X-linked adrenoleukodystrophy (X-ALD).

 

A genetic mutation in the evolution of animals explains the origin of some human organs Blog Post

A neutral genetic mutation –a fluke in the evolutionary process with no apparent biological purpose– that appeared over 700 million years ago in biological evolution could help explain the origin of complex organs and structures in human beings and other vertebrates, according to an article published in Nature Communications by a team led by Professor Jordi García-Fernàndez, from the Faculty of Biology of the University of Barcelona (UB) and the Institute of Biomedicine of the UB (IBUB) at the Barcelona Science Park (PCB), Manuel Irimia (CRG) and Maria Ina Arnone (Anton Dohrn Zoological Station, Italy).

 

The PCB receives the secondary award for best practice in science and technology parks of APTE Blog Post

Ignasi Belda, CEO of the Barcelona Science Park (PCB), has received this morning the secondary prize of the ‘Award for best practice in science and technology parks of Apte’ in the category of parks with an age of more than 10 years. The award ceremony has been delivered within the framework of the XV International Conference of the Association of Science and Technology Parks of Spain (APTE), which is being held today at the Gipuzkoa Science and Technology Park under the name “Beyond 2020: disruptive technologies“.

 

Esteve closes the Board of Directors renewal process with the appointment of Joan Esteve as a Chairman Blog Post

Esteve has just announced changes to its corporate governing bodies. In line with the plan approved by the Group’s Board, Albert Esteve will replace Joan Esteve as Chairman of the Board and announces the appointment of Staffan Schüberg, executive vicepresident of the Danish pharmaceutical company Lundbeckas, the group’s Chief Executive Officer. Since 2012, all discovery and preclinical development key units of Esteve are located at the Barcelona Science Park with the latest infrastructure and technology in a top-level academic and scientific environment in Spain.

 

An increase in low density lipoproteins would favour insulin resistance Blog Post

A study led by the University of Barcelona proved that low-density proteins (VLDL) can worsen insulin resistance, a disease that favours the development of type 2 diabetes. The study, published in the scientific journal Diabetologia , has been carried out by the research group led by Manuel Vázquez Carrera, researcher from the Department of Pharmacology, Toxicology and Therapeutic Chemistry and the Institute of Biomedicine of the UB (IBUB), located at the Barcelona Science Park.